iBio Inc. has announced an extension of the maturity date for its $1.5 million promissory note with Safi Biotherapeutics Inc. Originally set to mature on June 19, 2025, the note's maturity date has now been extended to June 19, 2026. As part of the agreement, iBio Inc. will ensure all accrued interest is paid at the time of the extension. This strategic move allows the company additional time to manage its financial obligations effectively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.